Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma

Vincent Rajkumar, S.; Rosiñol, Laura; A. Hussein, Mohamad; Catalano, John; Wiktor-Jędrzejczak, W; M. Lucy, Lela; Olesnyckyj, Marta; Yu, Zhinuan; Knight, Robert; B. Zeldis, Jerome; Bladé, Joan

doi:10.1200/jco.2007.14.1853

Public

Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma

Published in Journal of Clinical Oncology • Mar 25, 2008

Authors:

S. Vincent Rajkumar

Laura Rosiñol

Mohamad A. Hussein

Abstract

PURPOSE: The long-term impact of thalidomide plus dexamethasone (thal/dex) as primary therapy for newly diagnosed multiple myeloma (MM) is unknown. The goal of this study was to compare thalidomide plus dexamethasone versus placebo plus dexamethasone (placebo/dex)as primary therapy for newly diagnos...

Subject

Medicine

Dexamethasone

Thalidomide

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!